ARCHIVES

Cancer Research Faces A “Strategic Inflection,” NCI Director Says

This article is from The Cancer Letter archive.

Vol. 28 No. 16 | April 19, 2002

Download PDF Visit The Full Archive

Related Articles

In Brief: Calabresi Named DCT Board Chairman; NCI Gets $5 Million Gifts for Intramural Breast Cancer Work

June 20, 1986

Nexavar Improves PFS In Phase III Trial

January 25, 2013

NCI Proposal Would Give Drug Sponsors Commercial Rights To Biomarker Inventions

October 16, 2009

Grand Jury Clears Eppley, Shubik

October 24, 1980

Pilot Projects Scheduled To Begin Next Summer

December 4, 1998

NCI, DCT Board Cool Toward AMA, ACOS, VA Role In Clinical Trials

March 3, 1989